Published in Hepatitis Weekly, May 8th, 1995
HEV does not, however, pose a threat to the safety of the blood supply, indicated Patrice O. Yarbough, Ph.D., senior scientist, HEV Project Leader, Genelabs Technologies Inc., Redwood City, California. Yarbough addressed participants attending the Hepatitis - Latest Advances in the Diagnosis, Prevention and Treatment of HBV and HCV meeting April 20-21, 1995, in Washington, D.C.
"Our studies suggest that HEV is worldwide in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (1995-05-08)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.